Summary Enhanced DNA repair has been observed in cisplatin-resistant ovarian cancer cell lines. This resistance can be modulated, on co-incubation with aphidicolin in established cell lines and animal tumour models, by inhibiting DNA polymerases. We describe a study of the in vitro modulation effect of aphidicolin on cisplatin and carboplatin using fresh cells harvested from biopsy samples or ascitic fluids from 25 patients with ovarian adenocarcinoma. The MTT assay was used to measure cell survival after drug exposure. Aphidicolin (up to 30 pM) showed no cytotoxicity when tested alone. Forty-seven comparisons were made between drug with and without aphidicolin, and 37 (79%) cases demonstrated a significant increase in sensitivity to the platinum agents on co-incubation. Overall, there was a median 10-fold (range 1.64-to 58.5-fold) increase in sensitivity. When patients were grouped according to in vitro sensitivity to platinum, aphidicolin had a significantly greater effect in the 'resistant' group, causing a median 13.5-fold increase in sensitivity compared with 2.4-fold in the 'sensitive' group. Furthermore, a positive correlation between the LC50 for platinum and the corresponding fold increase in sensitivity suggests that aphidicolin overcomes platinum resistance in fresh cells from primary tumours. These results encourage the further development of this interesting compound.
Ovarian cancer is the most lethal of the gynaecological cancers (Kaye, 1993) , with an overall 5 year survival rate of less than 30% (Ozols, 1992) . Patients usually present late (FIGO stage III -IV) and are commonly treated with a platinum-based regime after cytoreductive surgery. Drug resistance remains a major limitation to treatment of this disease.
Several mechanisms leading to cellular resistance to the platinum agents have been identified in cells from ovarian cancer (see Friedlander, 1992 for review). Enhanced DNA repair has been found in platinum-resistant cell lines including the ovarian cancer cell line A2780/CP (Masuda et al., 1988) , and therefore this has been postulated as an important mechanism of resistance in this disease. Aphidtcolin, a tetracyclic diterpenoid antibiotic obtained from Cephalosporium aphidicola, has been shown to inhibit DNA repair by adhering to nucleotide-binding sites on DNA polymerase a and 6 and so prevent long-patch excision repair of platinum-induced DNA lesions (Beketic-Oreskovic and Osmak, 1995) . When co-incubated with cisplatin, aphidicolin has been shown to increase the cytotoxicity of this agent (Masuda et al., 1988; Chao, 1994) .
Preclinical studies on aphidicolin suggested that it was cytotoxic in vitro with moderate anti-tumour activity in vivo. This led to a phase I study of aphidicolin glycinate, a watersoluble analogue of aphidicolin (Sessa et al., 1991) . A continuous infusion over 24 h led to a maintained plasma level similar to that required for in vitro modulation of cisplatin but, when given as a single agent, aphidicolin had no anti-tumour effect. Local toxicity was dose limiting, while other toxic effects were absent. A combination study with cisplatin was suggested owing to the encouraging in vitro results of this combination. However, this group ran concomitant in vivo anti-tumour studies in mice, combining aphidicolin glycinate with cisplatin using as a model M5076 (M5), a murine reticular cell sarcoma line which is cisplatin sensitive, together with the cisplatin-resistant subline M5/ DDP (Damia et al., 1992 More recently, however, O'Dwyer et al. (1994) found significant potentiation of cisplatin by aphidicolin in vivo using the OVCAR-3 cell line, which was derived from a patient refractory to cisplatin, as a xenograft.
Information on the behaviour of platinum-resistant ovarian cancer cells has originated mainly from cell line studies and in vivo animal models. To understand the relevance of these cellular mechanisms of resistance in primary tumours, it is important to study platinum resistance in fresh cells from patients with ovarian cancer (Wilson et al., 1990; Sargent et al., 1994a) . This study aims to determine the effect of aphidicolin on cisplatin sensitivity in vitro using cells from patients with ovarian cancer, both on presentation and after previous cytotoxic therapy.
Materials and methods Patients
Fourteen ascitic fluid and 11 biopsy samples from primary tumours or metastatic sites were collected aseptically, at operation or by paracentesis, from 25 patients with histologically confirmed ovarian adenocarcinoma. Twentythree of these patients had advanced disease (FIGO stage III -IV). Fifteen patients had de novo disease and therefore had not received any cytotoxic therapy previously. Ten patients had a recurrence after previous treatment with cytotoxic agents.
Cells were separated from ascitic fluids by centrifugation and from solid biopsy samples using mechanical disaggregation with crossed scalpels and needle aspiration. Contaminating red blood cells and necrotic cells were removed by density-gradient centrifugation using lymphocyte separation medium (Histopaque, Sigma). A final cell suspension (1 x 106 cells ml-') was prepared in RPMI-1640, 10% fetal calf serum (FCS) and antibiotics. The morphology was assessed on cytospin preparations using May-Grunwald-Giemsa staining. Tumour cell number varied between samples, the median being 50% (range 2-90). In vitro sensitivity and calculation of modulation effect
The MTT assay was used to measure cell survival after drug exposure. The method used was similar to that previously described (Wilson et al., 1990) . After drug exposure, 50 jil of a 2 mg ml-' solution of MTT in phenol red free balanced salt solution was added to each well and the plate was incubated for a further 4 h. Any formazan crystals formed were dissolved in acid/alcohol (0.04 N hydrochloric acid in isopropanol) and the plate was read at 570 nm (reference 690 nm). A dose-response curve was drawn for each experiment and the LC50 (concentration required for 50% cell kill) calculated or predicted using our own customised software. In Modulation by aphidicolin There was a variation in the modulation ability of aphidicolin between patients (Figure 1) . Overall, 47 comparisons (only one comparison was possible in three patients, owing to lack of cells) were made between the effect of drug±aphidicolin and 37 (79%) of these demonstrated a significant increase in sensitivity to the platinum agents on co-incubation (Table I) . , carboplatin alone; ----, effect of co-incubation with aphidicolin in individual patients. Although there was a slight increase in the incidence of modulation in the group of patients who had received previous cytotoxic therapy (85%, compared with 74% in untreated patients), this difference did not reach significance (P> 0.1, Table I ). Similarly, when looking at the frequency of modulations independent of their size, 83% of the group of patients showing in vitro resistance to the platinums showed significant modulation compared with 67% in the in vitro sensitive group (P>0.1).
Sensitivity ratios
Sensitivity ratios comparing the LC50 for drug with and without aphidicolin were used to measure the size of the modulation effect. There was a median 10-fold (range 1.64-58.5) increase in sensitivity overall.
When patients were grouped according to in vitro sensitivity to the platinum drugs, there was a significant increase (P<0.01) in the sensitivity ratio in the resistant group (13.5-fold compared with 2.4-fold for the sensitive group, Figure 2 ). This was confirmed by a positive correlation between the LC50 and the sensitivity ratio for both cisplatin (rs=0.505, n=20, P<0.05) and carboplatin (rs = 0.637, n = 17, P< 0.02).
There was no significant difference in the modulating effect of aphidicolin on either cisplatin or carboplatin cytotoxicity.
Discussion
Inhibition of DNA repair occurring after damage by platinum agents has been postulated as a method of overcoming drug resistance in ovarian cancer. Most previous studies have been conducted using established cell lines or animal tumour models. To our knowledge, this is the first report of the in vitro effect of combining aphidicolin with the platinum agents in fresh cells from human ovarian tumours. Figure 2 The range of sensitivity ratios (LC50 of drug alone/ LC50 for drug + aphidicolin) obtained. There was a significant increase in the median of the group of patients found resistant in vitro to platinum compared with those found sensitive (from a 2.4-fold to a 13.5-fold increase in sensitivity), P<0.01.
We found that cells harvested from 22 of 25 patients showed markedly increased cytotoxicity to the platinum drugs on coincubation with aphidicolin. It has been widely reported that dose escalation of platinum treatment leads to improved response rates in ovarian cancer (Kaye et al., 1992) . The modulatory approach demonstrated in this study could translate into increased response rates without elevating the dose of cytotoxic drug.
Of particular interest was the finding that the modulatory effect of aphidicolin was significantly greater in cells demonstrating in vitro resistance to the platinum agents, suggesting the presence of enhanced DNA repair capability. Contrary to the report from another group using established ovarian cancer cell lines (Eastman and Schulte, 1988) , we found a positive correlation between the level of in vitro platinum resistance and the fold increase in sensitivity on coincubation with aphidicolin. These results suggest that, as cells become more resistant there is an enhanced capacity to repair DNA lesions, allowing an increased modulatory effect through the inhibition of DNA polymerase activity.
There is clear evidence in the literature of differing degrees of platinum resistance modulation by aphidicolin both in vitro (Masuda et al., 1988; Dempke et al., 1991) and in in vivo murine models (Damia et al., 1992; O'Dwyer et al., 1994) . So it appears that results vary according to cell line and, indeed, it has already been postulated that these variations may be related to DNA repair potential (Perez et al., 1993) . Our results using fresh cells from individual patients further confirm this hypothesis.
Not all the primary tumours tested showed significantly improved platinum cytotoxicity on co-incubation with aphidicolin, with 21% of cases showing no modulatory effect. Perhaps these cells do not have an enhanced DNA repair capacity and other mechanisms of drug resistance are involved. In vitro screening before treatment could help identify the group of patients who may benefit from the combination regimen. It was interesting to note that aphidicolin was equally effective in modulating resistance to cisplatin and carboplatin, thus confirming the sensitivity of these in vitro chemosensitivity assays.
A note of caution should always be applied when extrapolating in vitro experiments to the clinical situation. The final cell preparations contained a heterogeneous mixture of tumour cells with attendant stromal cells produced in response to the tumour. However, it has been repeatedly shown that DNA adduct formation in response to platinum therapy is similar in normal cells and tumour cells (Reed et al., 1987; Hengstler et al., 1992) . Indeed, the measurement of adducts in WBCs has been suggested as an in vitro measure of clinical response to therapy. Another potential shortcoming is the use of largely non-dividing cells for the study of DNA damage and repair, most of the cells from these samples being quiescent, recruitable cells. However, DNA adducts are formed in both dividing and non-dividing cells on exposure to platinum (Eastman, 1990) . Furthermore, as only a small proportion of cells from primary tumours are actively cycling in vivo (Parkinson, 1996) , these in vitro experiments may be more clinically relevant than those using actively dividing cell lines.
Another reason why we might be finding increased positive effects compared with some previous studies is that we were testing the compound itself, not the glycinate ester. It has been reported, however, that their effects are similar in vitro (Damia et al., 1992) .
The concentration of aphidicolin required for in vitro modulation is clinically achievable (Sessa et al., 1991) Further studies to measure DNA adduct formation in these cells from primary tumours along with normal WBCs from the same individuals after incubation in platinum agents with and without aphidicolin could prove interesting. Also, the measurement of the rate of removal of these adducts may help in the interpretation of these results. However, a recent study looking at the potentiation of temozolomide by poly(ADP-ribose) polymerase inhibitors found a disparity between the effect of the inhibitors on cell survival and their effect on DNA strand break repair. A higher concentration of inhibitor was required to affect strand break levels after exposure to temozolomide than was required to increase cytotoxicity. The authors concluded that this polymerase may be involved in DNA damage-inducible responses and so the concentration required to inhibit these differing actions may vary (Boulton et al., 1995) . This suggests that the measurement of effect on cytotoxicity is the most specific option.
Modulation of other mechanisms of cellular resistance to the platinum drugs in primary tumours, e.g. through the glutathione pathway or mediation of oncogene expression, has shown only limited success both in vitro (Sargent et al., 1994b) and when applied to the clinic (Morgan et al., 1995; O'Dwyer et al., 1996) . If a resistance modulation approach is going to make a significant contribution to the treatment of this devastating disease, alternative and more effective modulating agents such as aphidicolin must make the transition to the clinic.
